Curcumin Colon-Release Matrix with Gastroresistant Coating

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current curcumin formulations for treating intestinal disorders suffer from poor bioavailability and unsatisfactory release profiles, with rapid conjugation and accumulation in the digestive apparatus, leading to inadequate distribution and activity throughout the colonic tract.

Innovation Solution

Modified-release compositions incorporating curcumin in hydroxypropylmethylcellulose matrices with a gastroresistant coating, allowing for controlled and gradual release over 8-24 hours, ensuring homogenous distribution in the colon and maximizing pharmacological effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If curcumin is administered orally in conventional formulations, then it reaches the digestive apparatus, but it is rapidly conjugated to metabolites with lower biological activity and accumulates in tissues

Engineering Contradiction:
ImprovebioavailabilityVSAvoidrelease time
Core Design Contradiction:
ReliabilityVSDuration of action of moving object

Solution Approach 1:

The curcumin release system is segmented into multiple functional layers: a gastroresistant coating layer that protects curcumin during gastric transit, and a matrix core containing hydroxypropylmethylcellulose that provides controlled release in the colon. This segmentation allows the formulation to survive stomach conditions and then release curcumin gradually in the target location, resolving the contradiction between reaching the digestive apparatus and maintaining bioavailability.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The gastroresistant coating is applied preliminarily to protect curcumin from premature release and degradation in the stomach. This preliminary protective action ensures that curcumin remains intact during gastric transit and only becomes available for absorption after reaching the colon, thereby improving bioavailability and preventing premature metabolism.

Inventive Principle:
Principle #10Preliminary action

2Reliability

If curcumin is released immediately upon reaching the intestine, then absorption may occur, but distribution throughout the colonic tract is inadequate and homogenous

Engineering Contradiction:
Improvedistribution homogeneityVSAvoidrelease speed
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The release system transitions from a static protected state during gastric transit to a dynamic controlled release state in the colon. The matrix core's hydroxypropylmethylcellulose structure dynamically modulates curcumin release over time, providing sustained delivery throughout the colonic tract. This dynamic release mechanism ensures homogeneous distribution by maintaining curcumin availability across different colonic regions rather than releasing it all at once.

Inventive Principle:
Principle #15Dynamics

Solution Approach 2:

The formulation changes the release parameter from rapid/immediate to slow/controlled by using the matrix core structure. The hydroxypropylmethylcellulose matrix controls the diffusion rate of curcumin, transforming the release kinetics to achieve gradual distribution throughout the colon, thereby improving homogeneity of distribution while maintaining adequate release speed.

Inventive Principle:
Principle #35Parameter changes

3Reliability

If a gastroresistant coating is applied to prevent premature release, then curcumin protection is improved, but release control in the colon requires additional matrix structure

Engineering Contradiction:
Improveprotection from premature releaseVSAvoidformulation structure
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The formulation merges two protective mechanisms into a unified structure: the gastroresistant coating provides gastric protection while the matrix core simultaneously provides both structural integrity and controlled release functionality in the colon. This merging reduces overall formulation complexity compared to using separate systems for gastric protection and colonic release control.

Inventive Principle:
Principle #5Merging (Combining)

Solution Approach 2:

The matrix core serves multiple functions universally: it provides structural support for the tablet, controls the release kinetics of curcumin, and facilitates homogeneous distribution in the colon. By making the matrix core multi-functional, the formulation avoids adding separate components for each function, thereby managing device complexity while achieving reliable protection and controlled release.

Inventive Principle:
Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The compositions provide a controlled, slow release of curcumin in the colon, enhancing its bioavailability and therapeutic effects for conditions like irritable bowel syndrome and Crohn's disease, with a gastroresistant coating preventing premature release in the stomach and ensuring prolonged activity in the colonic tract.

Implementation Method 1

a gastroresistant coating of core a), wherein the curcumin to hydroxypropylmethylcellulose weight ratio ranges from 4:1 to 2:1

Methodology Applied
Scientific EffectGastroresistant coating: Coatings

Implementation Method 2

The formulations according to the invention, characterised by a core with a monolithic matrix, are able to modulate, control and slow the release of the active ingredient within 8-24 hours

Methodology Applied
Scientific EffectDiffusion: Diffusion

Implementation Method 3

The gastroresistant coating of the core prevents release in vitro for at least 2 hours

Methodology Applied
Scientific EffectErosion: Erosion

Data Source

PatentEP3079674B1Modified-release therapeutic systems for oral administration of curcumin in the treatment of intestinal disorders
Publication Date: 2018.08.22 MOGON PHARMA

AI summary

Disclosed are colon-specific delayed-release pharmaceutical compositions comprising: a) a matrix consisting of hydrophilic substances wherein curcumin is dispersed; b) a gastroresistant or acid-resistant pH-independent coating with a lag time of matrix a).